company background image
EPIX

ESSA Pharma NasdaqCM:EPIX Stock Report

Last Price

US$3.47

Market Cap

US$152.9m

7D

6.8%

1Y

-71.0%

Updated

05 Dec, 2022

Data

Company Financials +
EPIX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

EPIX Stock Overview

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer.

ESSA Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ESSA Pharma
Historical stock prices
Current Share PriceUS$3.47
52 Week HighUS$14.88
52 Week LowUS$1.40
Beta2.04
1 Month Change3.58%
3 Month Change50.22%
1 Year Change-70.99%
3 Year Change-33.86%
5 Year Change-21.56%
Change since IPO-96.07%

Recent News & Updates

Recent updates

Shareholder Returns

EPIXUS BiotechsUS Market
7D6.8%3.2%1.1%
1Y-71.0%-6.5%-17.6%

Return vs Industry: EPIX underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: EPIX underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is EPIX's price volatile compared to industry and market?
EPIX volatility
EPIX Average Weekly Movement53.3%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: EPIX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 53% a week.

Volatility Over Time: EPIX's weekly volatility has increased from 28% to 53% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009n/aDavid Parkinsonhttps://www.essapharma.com

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

ESSA Pharma Inc. Fundamentals Summary

How do ESSA Pharma's earnings and revenue compare to its market cap?
EPIX fundamental statistics
Market CapUS$152.93m
Earnings (TTM)-US$37.34m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EPIX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$37.34m
Earnings-US$37.34m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did EPIX perform over the long term?

See historical performance and comparison